Onpattro
Payments companies reported to CMS as associated with Onpattro. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Onpattro, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Onpattro
These are the largest totals companies reported as associated with Onpattro. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Zubair Shah | Kansas City, KS | Advanced Heart Failure and Transplant Cardiology | $20,296.41 |
| Robert Gottlieb | Dallas, TX | Advanced Heart Failure and Transplant Cardiology | $14,979.88 |
| Ronald Zolty | Omaha, NE | Cardiovascular Disease | $14,910.37 |
| Christopher Bell | Tupelo, MS | Acute Care (Nurse Practitioner) | $12,820.16 |
| Michel Khouri | Durham, NC | Cardiovascular Disease | $12,578.24 |
| Naveen Bellam | Orlando, FL | Advanced Heart Failure and Transplant Cardiology | $11,131.97 |
| Olakunle Akinboboye | Laurelton, NY | Internal Medicine | $9,470.35 |
| Said Beydoun | Los Angeles, CA | Clinical Neurophysiology | $9,306.05 |
| Mazen Hanna | Cleveland, OH | Cardiovascular Disease | $8,516.45 |
| Robert Vescio | West Hollywood, CA | Hematology & Oncology | $8,443.92 |
Prescribed Onpattro?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.